JNNP 神经病学· Huang, W., Zhang, X., Wang, Z., ZhangBao, J., Zhou, L., Li, X., Tan, H., Dong, Q., Quan, C.·· 7 天前AI 评分56
Inebilizumab与传统免疫疗法治疗AQP4-IgG阳性NMOSD的前瞻性队列比较:复发风险与残疾进展的时变分析
Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects
AI 导读
该前瞻性队列研究对维持治疗初治的AQP4-IgG阳性视神经脊髓炎谱系障碍(NMOSD)患者进行比较,结果显示inebilizumab较硫唑嘌呤(AZA)和霉酚酸酯(MMF)与较低的复发风险和更慢的残疾进展相关。
来源:JNNP 神经病学 · jnnp.bmj.com